fostamatinib and efgartigimod: novel agents in the treatment of itp
Published 1 year ago • 208 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
2:57
novel targeted therapies for the treatment of bpdcn
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
3:24
novel agents for the management of r/r myeloma
-
1:59
novel investigational drugs and promising therapies for immune thrombocytopenia
-
2:02
how to ace your rheumatology interview
-
11:01
eltrombopag & paediatric chronic immune thrombocytopenia (itp) l pediatrics updates
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
1:10
upcoming novel agents for the treatment of sickle cell disease
-
37:22
eha 2024 recap: optimizing the relapsed/refractory cll treatment pathway
-
1:43
the changing treatment landscape of pnh: novel agents and combinations
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
2:25
novel ai model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
3:02
novel treatments and ongoing clinical trials for wm: targeted agents and immunotherapies
-
14:25
an overview of novel innovative treatments for patients with von willebrand disease
-
0:36
the potential of immunotherapies in the myeloma treatment landscape
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:22
protacs: potential novel agents for the treatment of cll
-
0:57
novel therapeutic strategies in all
-
2:56
novel drugs for myeloma thromboprophylaxis